Sanlam Launches Morocco's First Pet Health Insurance for Cats and Dogs
Whether it's an unexpected surgery or routine vaccinations, pet owners can now breathe easier.
The policy, open to animals aged between three months and 15 years, covers a wide range of veterinary expenses — from medical consultations and surgical procedures to hospital stays, lab tests, medications, and even preventive care like vaccines and deworming.
It's a comprehensive offer that comes in three tailored plans: Essentiel, Confort, and Premium, each offering different levels of reimbursement.
But the coverage doesn't stop there. In case of a pet's death, Sanlam offers a capped compensation payout based on the plan and the animal covered — a delicate but pragmatic touch in a market where the emotional and financial value of pets is increasingly recognized.
Subscription is fully digital and accessible either through the insurer's website or via its nationwide network of intermediaries.
The launch is a timely one. With rising awareness about animal welfare and the growing financial burden of vet visits, Moroccan pet owners are now looking for real solutions — and Sanlam, it seems, has just offered one.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Morocco World
14 hours ago
- Morocco World
Casablanca's Oncorad Publishes 1st African Prostate Cancer Research in Leading U.S. Journal
Rabat – The Casablanca-based Oncorad Group has become the first cancer treatment center in Africa to publish research in 'Advances in Radiation Oncology,' in partnership with the American Society for Radiation Oncology (ASTRO). The featured study, carried out by Oncorad's research team at the Le Littoral Clinic, explores a combined treatment protocol for aggressive prostate cancer, integrating high-dose-rate (HDR) brachytherapy with external beam radiotherapy. Conducted on a cohort of more than 120 patients, including several international cases, the research demonstrated a 92% remission rate with no significant toxicity. These results are consistent with the highest global standards in cancer care. The project was developed by a multidisciplinary Moroccan team led by principal investigator Dr. Hamza Samlali and coordinated by Dr. Najlaa Assaid. The medical physics team included Youness Khobbaizi, Omar Hanicha, Mahdi Abou El Houda, and Sanaa Nabil, under the leadership of Professor Redouane Samlali, founder of Oncorad Group. The initiative also received academic support from Professor Hassan Jouhadi, head of oncology at the University Hospital of Casablanca and professor at the city's Faculty of Medicine. Read also: Oncorad Group Celebrates First Cryoablation Procedure in Morocco, North Africa This publication represents the largest clinical series of its kind from Africa and the MENA region and positions Oncorad as a leading regional actor in cancer treatment and research. The study's inclusion of international patients further underscores its transnational relevance. Beyond this achievement, Oncorad's research unit continues to pursue a wide range of projects focused on locally adapted, innovative cancer care solutions. These include advances in robotic surgery, state-of-the-art radiotherapy techniques, and investigations into the genetic and biological dimensions of cancer—all supported through collaborations with national and international partners. Advances in Radiation Oncology is globally recognized for promoting impactful clinical research, particularly from resource-limited settings. With an impact factor of 2.7 and listings in leading databases such as PubMed Central, Scopus, and Web of Science, the journal's publication of Oncorad's study marks a significant milestone for African contributions to global medical literature. By bringing African data and perspectives to the forefront of scientific dialogue, Oncorad aims to support the development of more inclusive, evidence-based treatment strategies that benefit cancer patients across low- and middle-income countries. Tags: HealthOncoradProstate Cancer
Ya Biladi
a day ago
- Ya Biladi
Mohammed VI Foundation and AstraZeneca partner to enhance rare disease care in Morocco
The Mohammed VI Foundation for Science and Health (FM6SS) and AstraZeneca signed a memorandum of understanding on Wednesday in Rabat to jointly develop Centers of Excellence for rare diseases, aiming to strengthen Morocco's healthcare ecosystem and improve care for patients affected by these conditions. This partnership is part of a broader initiative to provide innovative solutions to patients by facilitating earlier diagnosis, improving access to treatment, and enhancing training for healthcare professionals. It includes the development of advanced diagnostic platforms, the integration of cutting-edge technologies in genetic testing, and the creation of multidisciplinary hubs for care, research, and education. In a statement to MAP, Saber Boutayeb, Director of the Mohammed VI Center for Research and Innovation, said the agreement marks the culmination of a collaborative effort with AstraZeneca at the regional level, extending beyond Morocco. Rami Scandar, AstraZeneca's Regional President for the Near East and Maghreb, emphasized that the partnership is built around five key pillars. The first is reducing the average diagnostic time for rare diseases, which can currently take up to five years, thereby improving patient outcomes. The second involves creating genetic testing platforms in collaboration with the Foundation. The third pillar focuses on training doctors, nurses, and caregivers to strengthen support for patients with rare conditions. The fourth addresses equitable access to treatment by introducing medications priced appropriately for the Moroccan context, in coordination with the Ministry of Health. Finally, the fifth pillar seeks to improve epidemiological knowledge of rare diseases in Morocco through data collection and scientific monitoring. This agreement further reinforces AstraZeneca's long-term commitment to sustainable growth and partnership in Morocco. Building on previous successful collaborations with the Mohammed VI Foundation for Science and Health, the two parties are charting a shared path to address unmet medical needs and deliver a lasting, tangible impact for patients across the Kingdom.
Morocco World
2 days ago
- Morocco World
Sothema Acquires Soludia Maghreb in MAD 1 Billion Deal
Marrakech – Pharmaceutical group Sothema, led by CEO Lamia Tazi, has finalized an agreement to acquire 99.99% of Soludia Maghreb's capital, valued at nearly MAD 1 billion ($100 million). The deal was reached with Soludia's historical shareholders: Abdelaziz Razkaoui, Cap Mezzanine III fund managed by CDG Invest Growth, and the Zine family. Founded in 1996, Soludia Maghreb has established itself as a leading industrial player in hemodialysis in Morocco. The company manufactures essential hemodialysis products, including powdered bicarbonate cartridges and liquid acid and bicarbonate solutions. Soludia also distributes pharmaceutical specialties for international partners and holds 40% of Hidropura Maroc, a company specializing in the installation and maintenance of acid plants and water treatment systems for hemodialysis centers. According to 2025 projections, Soludia is expected to generate revenue of MAD 360 million ($36 million) and an adjusted EBITDA of MAD 90 million ($9 million), excluding post-acquisition synergies. An additional price of MAD 95 million ($9.5 million) may be paid, contingent on meeting specific financial objectives. As part of the agreement, Abdelaziz Razkaoui will continue to serve as Soludia's CEO for a minimum period of five years, ensuring management continuity. Razkaoui and CDG Invest Growth chose to convert 80% of their shares in Soludia into Sothema shares instead of opting for a cash payment – a move that reflects their confidence in the group's long-term vision and leadership. The remaining cash payment amounts to approximately MAD 365 million ($36.5 million). Sothema has confirmed that no capital increase will be necessary to finance this transaction. A bold advance in Sothema's industrial strategy With this acquisition, Sothema estimates its 2025 consolidated revenue at about MAD 3.5 billion ($350 million) and consolidated EBITDA exceeding MAD 800 million ($80 million). This strategic acquisition represents a bold advance in Sothema's industrial strategy, reinforcing its therapeutic portfolio in a sector regarded as critical to public health, according to their press release. The deal aims to enhance national industrial capabilities in hemodialysis, expand Sothema's therapeutic portfolio in a segment with high public health impact, and increase Soludia's competitiveness in international markets, particularly in West Africa and the Middle East. Established in 1976, Sothema is a key player in the Moroccan pharmaceutical industry. The group has partnerships with around forty leading international R&D laboratories and develops its own ranges of generics, biosimilars, and medical devices, with an extensive presence across Africa and the Arab world. The completion of the transaction remains subject to the fulfillment of customary closing conditions, particularly approval from the Competition Council. The closing is expected before the end of 2025. Tags: pharmaceutical industry in MoroccoSothema
